San Francisco, California, November 06, 2017: The growing number of cases where there exists symptoms associated with brain tumor has led to a need for tests which can detect the presence of tumors, .states TMR Research in its latest report. The report is titled “Brain Tumor Diagnostics and Therapeutics Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025.” According to the report the brain tumor diagnostics and therapeutics market is witnessing a high growth on account of the growing prevalence of brain cancer, widespread market for the treatment of brain cancer and associated symptoms, as well as innovations in drug delivery. Some of the most commonly used tests for the diagnosis of Brain Tumor include magnetic reasoning imaging (MRI), biopsy or tissue sampling, CT scan, electroencephalography (EEG), cerebral angiogram of cerebral anteriogram, positron emission tomography (PET), molecular testing, and neuro cognitive assessment.
According to the report, the trend of public private partnerships in the healthcare sector will prove to be beneficial for the growth of the brain tumor diagnostics and therapeutics market because this is enabling the modernization of radiology and diagnostic imaging services. Another factor which will boost the growth of the market is the increasing research activities in the area of molecular diagnostics that are aimed at cell biology and recognizing gene mutations related to malignancy. Other growth drivers for the market include increasing consumer base, technological advancements, advanced healthcare infrastructure, and increasing awareness and concern among people regarding their health.
The report not only discusses the growth drivers but also discusses the various factors that are expected to challenge the growth trajectory of the brain tumor diagnostics and therapeutics market. One of the key factors that is expected to deter the market’s growth is the high cost of these tests. Another factor that will restrain the growth of the market is the lack of trained personnel. The growing use of generics in chemotherapy and the lack of brain cancer specific drug other factors that will hamper the growth of the market. However, various growth opportunities are expected to emerge on account of the development of new technologies such as sodium magnetic resonance imaging (Na MRI) and chemical exchange saturation transfer (CEST). These technologies assist the therapies treating the tumor as well as in the diagnosis of tumors. It is also expected that the improvement in technology will enable access to cancer tumors at unreachable parts of the brain.
On the basis of geography, North America is expected to be the leading regional segment, with the US in the forefront. As per the Central Brain Tumor Registry, there have been approximately 79,270 new cases of primary non malignant and malignant brain and CNS tumors in the year 2017. This growing incidence of brain tumor in the country is expected to drive the growth of the North American brain tumor diagnostics and therapeutics market. Apart from North America, it is expected that Asia Pacific will expand at a favorable pace during the forecast period on account of the growing awareness among the patients about the availability and significance of these tests. The health expenditure and the income of people in Asia Pacific is increasing and this is expected to further expand the growth of the brain tumor diagnostic and therapeutic market.
The report segments the market based on types of tumor into: the anaplastic astrocytoma, low-grade (diffuse) astrocytoma, anaplastic oligodendroglioma, ependymoma, oligodendroglioma, and glioblastoma.
The report profiles key players within the brain tumor diagnostics and therapeutics market for the purpose of study. Some of them are: Roche Diagnostics, Philips Healthcare, GE Healthcare, Carestream Health, Toshiba Corporation, Bristol Myer Squibb, Siemens Healthineers, and Hitachi, Ltd.
Get Sample Brochure of this Report Study